Table 4.

Estimates of change from baseline in high-density lipoprotein particle size

Variable	1 mg/d	5 mg/d	15 mg/d	Placebo	P, 5 mg/d vs placebo	P, any effect
Extra-small HDL subspecies, nm	0.024 (–0.023 to 0.072)	0.014 (–0.032 to 0.060)	0.027 (–0.018 to 0.072)	–0.012 (–0.058 to 0.034)	.403	.586
Small HDL subspecies, nm	0.002 (–0.043 to 0.046)	0.019 (–0.025 to 0.062)	0.012 (–0.031 to 0.054)	–0.001 (–0.044 to 0.043)	.509	.902
Medium HDL subspecies, nm	0.006 (–0.060 to 0.071)	0.004 (–0.059 to 0.067)	–0.007 (–0.068 to 0.055)	0.005 (–0.059 to 0.068)	.991	.992
Medium-large HDL subspecies, nm	–0.006 (–0.055 to 0.439)	0.060 (0.012 to 0.108)	0.031 (–0.017 to 0.079)	0.036 (–0.013 to 0.084)	.455	.251
Large HDL subspecies, nm	–0.019 (–0.091 to 0.539)	–0.028 (–0.098 to 0.042)	–0.016 (–0.085 to 0.053)	0.035 (–0.035 to 0.106)	.185	.541
Extra-large HDL subspecies, nm	–0.046 (–0.151 to 0.059)	0.050 (–0.049 to 0.150)	–0.005 (–0.103 to 0.094)	–0.019 (–0.119 to 0.081)	.300	.541

Estimated changes from baseline, 95% CIs, and P values extracted from ANCOVA framework. P values are for comparison of the 5 mg/day arm with placebo group and for the test of any difference between groups in average change over 12-week follow-up.

Abbreviations: ANCOVA, analysis of covariance; HDL, high-density lipoprotein.